Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

S. Michiels; L. Pugliano; S. Marguet; D. Grun; J. Barinoff; David Cameron; M. Cobleigh; A. Di Leo; S. Johnston; G. Gasparini; B. Kaufman; M. Marty; V. Nekjudova; S. Paluch-Shimon; F. Penault-Llorca; D. Slamon; C. Vogel; G. Von Minckwitz; M. Buyse; M. Piccart

doi:10.1093/annonc/mdw132

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

S. Michiels, L. Pugliano, S. Marguet, D. Grun, J. Barinoff, David Cameron, M. Cobleigh, A. Di Leo, S. Johnston, G. Gasparini, B. Kaufman, M. Marty, V. Nekjudova, S. Paluch-Shimon, F. Penault-Llorca, D. Slamon, C. Vogel, G. Von Minckwitz, M. Buyse, M. Piccart

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Annals of Oncology
DOIs	https://doi.org/10.1093/annonc/mdw132
Publication status	Published - 8 Mar 2016

Access to Document

10.1093/annonc/mdw132

preprint manuscript pfs surrog HER2 MBC 2402016
This article has been accepted for publication in The Annals of Oncology 2016 Published by Oxford University Press.
Accepted author manuscript, 222 KB

Cite this

Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Di Leo, A., Johnston, S., Gasparini, G., Kaufman, B., Marty, M., Nekjudova, V., Paluch-Shimon, S., Penault-Llorca, F., Slamon, D., Vogel, C., Von Minckwitz, G., Buyse, M., & Piccart, M. (2016). Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdw132

Michiels, S. ; Pugliano, L. ; Marguet, S. ; Grun, D. ; Barinoff, J. ; Cameron, David ; Cobleigh, M. ; Di Leo, A. ; Johnston, S. ; Gasparini, G. ; Kaufman, B. ; Marty, M. ; Nekjudova, V. ; Paluch-Shimon, S. ; Penault-Llorca, F. ; Slamon, D. ; Vogel, C. ; Von Minckwitz, G. ; Buyse, M. ; Piccart, M. / Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. In: Annals of Oncology. 2016.

@article{11af6e5a7d2c42659b7893efb64402da,

title = "Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer",

author = "S. Michiels and L. Pugliano and S. Marguet and D. Grun and J. Barinoff and David Cameron and M. Cobleigh and {Di Leo}, A. and S. Johnston and G. Gasparini and B. Kaufman and M. Marty and V. Nekjudova and S. Paluch-Shimon and F. Penault-Llorca and D. Slamon and C. Vogel and {Von Minckwitz}, G. and M. Buyse and M. Piccart",

year = "2016",

month = mar,

day = "8",

doi = "10.1093/annonc/mdw132",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Michiels, S, Pugliano, L, Marguet, S, Grun, D, Barinoff, J, Cameron, D, Cobleigh, M, Di Leo, A, Johnston, S, Gasparini, G, Kaufman, B, Marty, M, Nekjudova, V, Paluch-Shimon, S, Penault-Llorca, F, Slamon, D, Vogel, C, Von Minckwitz, G, Buyse, M & Piccart, M 2016, 'Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer', Annals of Oncology. https://doi.org/10.1093/annonc/mdw132

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. / Michiels, S.; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, David; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekjudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; Von Minckwitz, G.; Buyse, M.; Piccart, M.

In: Annals of Oncology, 08.03.2016.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

AU - Michiels, S.

AU - Pugliano, L.

AU - Marguet, S.

AU - Grun, D.

AU - Barinoff, J.

AU - Cameron, David

AU - Cobleigh, M.

AU - Di Leo, A.

AU - Johnston, S.

AU - Gasparini, G.

AU - Kaufman, B.

AU - Marty, M.

AU - Nekjudova, V.

AU - Paluch-Shimon, S.

AU - Penault-Llorca, F.

AU - Slamon, D.

AU - Vogel, C.

AU - Von Minckwitz, G.

AU - Buyse, M.

AU - Piccart, M.

PY - 2016/3/8

Y1 - 2016/3/8

U2 - 10.1093/annonc/mdw132

DO - 10.1093/annonc/mdw132

M3 - Article

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -